vs

Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Penguin Solutions, Inc. (PENG). Click either name above to swap in a different company.

Penguin Solutions, Inc. is the larger business by last-quarter revenue ($343.1M vs $339.0M, roughly 1.0× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs 1.5%, a 11.7% gap on every dollar of revenue. On growth, Penguin Solutions, Inc. posted the faster year-over-year revenue change (0.6% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $28.2M). Over the past eight quarters, Penguin Solutions, Inc.'s revenue compounded faster (11.8% CAGR vs 0.4%).

Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.

The Lampo Group, LLC, doing business as Ramsey Solutions, is an American company that provides products and services relating to personal finance, leadership development, interpersonal relationships, and professional development. Founded in 1991 by Dave Ramsey and his wife, Sharon, the company is based in Franklin, Tennessee.

HAE vs PENG — Head-to-Head

Bigger by revenue
PENG
PENG
1.0× larger
PENG
$343.1M
$339.0M
HAE
Growing faster (revenue YoY)
PENG
PENG
+3.3% gap
PENG
0.6%
-2.7%
HAE
Higher net margin
HAE
HAE
11.7% more per $
HAE
13.2%
1.5%
PENG
More free cash flow
HAE
HAE
$59.0M more FCF
HAE
$87.2M
$28.2M
PENG
Faster 2-yr revenue CAGR
PENG
PENG
Annualised
PENG
11.8%
0.4%
HAE

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
HAE
HAE
PENG
PENG
Revenue
$339.0M
$343.1M
Net Profit
$44.7M
$5.3M
Gross Margin
59.7%
28.0%
Operating Margin
19.9%
5.7%
Net Margin
13.2%
1.5%
Revenue YoY
-2.7%
0.6%
Net Profit YoY
19.3%
1.0%
EPS (diluted)
$0.95
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HAE
HAE
PENG
PENG
Q4 25
$339.0M
$343.1M
Q3 25
$327.3M
$337.9M
Q2 25
$321.4M
$324.3M
Q1 25
$330.6M
$365.5M
Q4 24
$348.5M
$341.1M
Q3 24
$345.5M
$284.8M
Q2 24
$336.2M
$300.6M
Q4 23
$336.3M
$274.2M
Net Profit
HAE
HAE
PENG
PENG
Q4 25
$44.7M
$5.3M
Q3 25
$38.7M
$9.4M
Q2 25
$34.0M
$2.7M
Q1 25
$58.0M
$8.1M
Q4 24
$37.5M
$5.2M
Q3 24
$33.8M
Q2 24
$38.4M
$5.6M
Q4 23
$31.2M
$-19.9M
Gross Margin
HAE
HAE
PENG
PENG
Q4 25
59.7%
28.0%
Q3 25
59.5%
28.6%
Q2 25
59.8%
29.3%
Q1 25
58.4%
28.6%
Q4 24
55.5%
28.7%
Q3 24
54.2%
28.8%
Q2 24
52.0%
29.6%
Q4 23
52.9%
30.2%
Operating Margin
HAE
HAE
PENG
PENG
Q4 25
19.9%
5.7%
Q3 25
17.9%
3.7%
Q2 25
16.8%
3.0%
Q1 25
21.6%
5.1%
Q4 24
16.9%
5.1%
Q3 24
15.0%
-1.2%
Q2 24
11.8%
3.8%
Q4 23
13.7%
0.5%
Net Margin
HAE
HAE
PENG
PENG
Q4 25
13.2%
1.5%
Q3 25
11.8%
2.8%
Q2 25
10.6%
0.8%
Q1 25
17.5%
2.2%
Q4 24
10.8%
1.5%
Q3 24
9.8%
Q2 24
11.4%
1.9%
Q4 23
9.3%
-7.3%
EPS (diluted)
HAE
HAE
PENG
PENG
Q4 25
$0.95
$0.04
Q3 25
$0.81
$0.10
Q2 25
$0.70
$-0.01
Q1 25
$1.17
$0.09
Q4 24
$0.74
$0.10
Q3 24
$0.66
Q2 24
$0.74
$0.10
Q4 23
$0.61
$-0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HAE
HAE
PENG
PENG
Cash + ST InvestmentsLiquidity on hand
$363.4M
$461.5M
Total DebtLower is stronger
$1.2B
$462.3M
Stockholders' EquityBook value
$911.5M
$389.7M
Total Assets
$2.5B
$1.6B
Debt / EquityLower = less leverage
1.34×
1.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HAE
HAE
PENG
PENG
Q4 25
$363.4M
$461.5M
Q3 25
$296.4M
$453.8M
Q2 25
$292.9M
$735.5M
Q1 25
$306.8M
$647.0M
Q4 24
$320.8M
$393.7M
Q3 24
$299.3M
$389.5M
Q2 24
$344.4M
$467.5M
Q4 23
$194.0M
$553.4M
Total Debt
HAE
HAE
PENG
PENG
Q4 25
$1.2B
$462.3M
Q3 25
$1.2B
$461.8M
Q2 25
$1.2B
$659.5M
Q1 25
$1.2B
$658.8M
Q4 24
$658.1M
Q3 24
$657.3M
Q2 24
$667.0M
Q4 23
$776.8M
Stockholders' Equity
HAE
HAE
PENG
PENG
Q4 25
$911.5M
$389.7M
Q3 25
$849.2M
$394.2M
Q2 25
$882.3M
$584.8M
Q1 25
$820.8M
$602.5M
Q4 24
$906.9M
$400.4M
Q3 24
$878.9M
$391.4M
Q2 24
$905.4M
$423.4M
Q4 23
$943.3M
$410.2M
Total Assets
HAE
HAE
PENG
PENG
Q4 25
$2.5B
$1.6B
Q3 25
$2.4B
$1.6B
Q2 25
$2.5B
$1.8B
Q1 25
$2.5B
$1.8B
Q4 24
$2.5B
$1.6B
Q3 24
$2.5B
$1.5B
Q2 24
$2.5B
$1.5B
Q4 23
$2.2B
$1.6B
Debt / Equity
HAE
HAE
PENG
PENG
Q4 25
1.34×
1.19×
Q3 25
1.44×
1.17×
Q2 25
1.39×
1.13×
Q1 25
1.49×
1.09×
Q4 24
1.64×
Q3 24
1.68×
Q2 24
1.58×
Q4 23
1.89×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HAE
HAE
PENG
PENG
Operating Cash FlowLast quarter
$93.6M
$31.1M
Free Cash FlowOCF − Capex
$87.2M
$28.2M
FCF MarginFCF / Revenue
25.7%
8.2%
Capex IntensityCapex / Revenue
1.9%
0.8%
Cash ConversionOCF / Net Profit
2.09×
5.89×
TTM Free Cash FlowTrailing 4 quarters
$308.1M
$116.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HAE
HAE
PENG
PENG
Q4 25
$93.6M
$31.1M
Q3 25
$111.3M
$-70.4M
Q2 25
$17.4M
$92.8M
Q1 25
$116.6M
$72.9M
Q4 24
$43.8M
$13.8M
Q3 24
$48.8M
Q2 24
$-27.4M
$57.9M
Q4 23
$-540.0K
$31.5M
Free Cash Flow
HAE
HAE
PENG
PENG
Q4 25
$87.2M
$28.2M
Q3 25
$106.3M
$-73.4M
Q2 25
$13.6M
$90.9M
Q1 25
$100.9M
$70.5M
Q4 24
$35.2M
$12.0M
Q3 24
$39.4M
Q2 24
$-33.1M
$48.9M
Q4 23
$-15.2M
$26.8M
FCF Margin
HAE
HAE
PENG
PENG
Q4 25
25.7%
8.2%
Q3 25
32.5%
-21.7%
Q2 25
4.2%
28.0%
Q1 25
30.5%
19.3%
Q4 24
10.1%
3.5%
Q3 24
11.4%
Q2 24
-9.8%
16.3%
Q4 23
-4.5%
9.8%
Capex Intensity
HAE
HAE
PENG
PENG
Q4 25
1.9%
0.8%
Q3 25
1.5%
0.9%
Q2 25
1.2%
0.6%
Q1 25
4.7%
0.6%
Q4 24
2.5%
0.5%
Q3 24
2.7%
Q2 24
1.7%
3.0%
Q4 23
4.4%
1.7%
Cash Conversion
HAE
HAE
PENG
PENG
Q4 25
2.09×
5.89×
Q3 25
2.88×
-7.47×
Q2 25
0.51×
34.88×
Q1 25
2.01×
9.02×
Q4 24
1.17×
2.65×
Q3 24
1.44×
Q2 24
-0.71×
10.30×
Q4 23
-0.02×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HAE
HAE

Hospital$143.5M42%
Plasma Productsand Services$138.9M41%
Blood Center Productsand Services$56.6M17%

PENG
PENG

Integrated Memory Segment$171.6M50%
Advanced Computing Segment$115.7M34%
Optimized LED Segment$55.7M16%

Related Comparisons